Crohn'
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Ileal, colonic, or ileocolonic Crohn's disease patients treated with biologics (anti-TNF agents, ustekinumab or vedolizumab)
Exclusion criteria
Exclusion criteria: 1) Patients with severe infection (sepsis, etc.) 2) Patients with active tuberculosis 3) Patients with history of hypersensitivity to the ingredient of anti-TNF antibody, ustekinumab, or vedolizumab, or the protein of mouse origin 4) Patients with demyelinating disease (multiple sclerosis, etc.) or with history of demyelinating disease 5) Patients with congestive heart failure 6) Patients treated with two or more biologics in combination 7) Patients under 16 years old 8) Patients judged as inappropriate by physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical remission and mucosal healing rates 52 weeks after the treatment with biologics | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of major adverse outcomes (hospitalization, surgery, discontinuation due to treatment failure) Factors associated with clinical remission, mucosal healing or major adverse outcomes | — |
Countries
Japan
Contacts
Tohoku University Hospital Division of Gastroenterology